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Abstract: This article is a summary of the publication ―Iron and Health‖ by the Scientific 
Advisory Committee on Nutrition (SACN) to the U.K. Government (2010), which reviews 
the dietary intake of iron and the impact of different dietary patterns on the nutritional and 
health status of the U.K. population. It concludes that several uncertainties make it difficult 
to determine dose-response relationships or to confidently characterize the risks associated 
with  iron  deficiency  or  excess.  The  publication  makes  several  recommendations 
concerning  iron  intakes  from  food,  including  meat,  and  from  supplements,  as  well  as 
recommendations for further research. 
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1. Introduction 
Iron deficiency and iron deficiency anemia are serious public health problems throughout the life 
cycle in both industrialized and developing countries, with negative consequences on maternal and 
child mortality, cognitive and physical development of children, and physical performance and work 
capacity in adults. Strategies to control deficiencies include dietary diversification, food fortification 
and iron supplementation. However there are concerns that increased iron intakes from high meat 
consumption, and iron fortification and supplementation may lead to increased risk of chronic diseases 
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including  cardiovascular  disease  and  cancer,  especially  in  sections  of  populations  with  genetic 
predispositions to iron overload.  
This article is based on the recently published review of Iron and Health by the Scientific Advisory 
Committee on Nutrition (SACN) to the UK government [1]. The review was undertaken following the 
recommendation of the previous advisory committee, the Committee on the Medical Aspects of Food 
and Nutrition Policy (COMA) in their report, Nutritional Aspects of the Development of Cancer [2] 
which had concluded that lower consumption of red and processed meat would probably reduce the 
risk of colorectal cancer. COMA recommended that intakes of red and processed meat should not rise, 
and  that  adults  with  intakes  greater than average  (then  estimated  to  be  90 g/day cooked  weight), 
especially those with high intakes, should consider a reduction in intake. Since red meat is a source of 
iron (as well as other micronutrients such as zinc) in the UK diet, COMA recommended that the 
―implications of a reduction in meat consumption on other aspects of health, particularly iron status‖ 
should be reviewed. 
However in view of the possibility that some subgroups of the U.K. population might be iron 
deficient, or be at risk of iron deficiency, and of possible adverse effects of increased iron intakes, 
consideration of iron nutrition in the U.K. population needs to be sensitive to the balance between iron 
deficiency and iron excess. 
The terms of reference of the SACN Iron Working Group were: 
To review the dietary intakes of iron in its various forms and the impact of different dietary 
patterns on the nutritional and health status of the population and to make proposals. 
Consideration of both beneficial and adverse effects of increasing iron intakes was undertaken, 
including: the effect of dietary components on iron absorption and utilization in the body; interactions 
of  infections  and  inflammation  with  iron  metabolism  and  the  possibility  that  this  may  affect  the 
apparent  incidence  of  iron  deficiency;  the  effect  of  iron  deficiency  on  health  and  well-being,  for 
example mental and physical development; potential adverse effects of excess iron, including free 
radical damage and the risk of cardiovascular disease (CVD) and cancer; as well as the associations 
between consumption of red and processed meat and cancer risk since these foods contain iron. These 
are summarized here. 
2. Biochemistry  
Iron (Fe) exists in two biologically relevant states: the reduced ferrous form (Fe
2+) and the oxidized 
ferric form (Fe
3+). Iron is an efficient catalyst for electron transfer and free-radical reactions which also 
means that ―free iron‖ (i.e., when it is not bound to protein or other organic molecules) is potentially 
toxic and that organisms need to minimize their exposure to it. This protection from exposure depends 
on proteins which are specifically involved in its uptake from the diet and its transfer into the systemic 
circulation, its transport around the body and storage in tissues, as well as its delivery to functional sites. 
3. Function 
Iron, as a component of hemoglobin in erythrocytes (red blood cells), is required for transporting 
oxygen around the body and, in the form of myoglobin, for the storage and use of oxygen in muscles. Nutrients 2011, 3  
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The oxygen released in the tissues from hemoglobin is used in oxidative metabolism. Hemoglobin 
binds carbon dioxide in the tissues and carries it to the lungs where it is exhaled.  
Table 1. Examples of functional iron-containing proteins in the body (75 kg man). 
Iron-containing protein  Function  Location  Iron content 
(mg) 
Heme proteins       
Hemoglobin  Oxygen transport  Red blood cells  3,000 
Myoglobin  Oxygen storage  Muscle  400 
Heme enzymes    All tissues  c 30 
Cytochromes a, b, c 
 
 
 
 
Cytochrome C oxidase 
Cytochrome P450 + b5 
Dcytb 
 
Catalase 
Peroxidases 
Myeloperoxidase 
 
Sulfite oxidase 
 
Tryptophan 2,3-dioxygenase 
Iodase (iodoperoxidase) 
Electron transfer 
Transfer of electrons to molecular oxygen at 
end of respiratory chain 
(also requires copper) 
 
Microsomal mixed function oxidases 
Phase I biotransformation of xenobiotics 
Ferrireductase (duodenal enterocytes) 
 
Hydrogen peroxide breakdown 
Peroxide breakdown 
Neutrophil bacteriocide 
 
Sulfites to sulfates 
 
Pyridine metabolism  
Iodide to iodate 
   
 
Non-heme iron enzymes 
   
All tissues 
 
c 30 
Ribonucleotide reductase 
 
(Iron-sulfur proteins) 
Aconitase 
Isocitrate dehydrogenase 
Succinate dehydrogenase 
NADH dehydrogenase 
 
Aldehyde oxidase 
Xanthine oxidase 
 
Phenylalanine hydroxylase 
Tyrosine hydroxylase 
Tryptophan hydroxylase 
 
Prolyl hydroxylase 
Lysyl hydroxylase 
Ribonucleotides → 2’-deoxyribnucleotides 
Synthetic phase of cell division 
 
Citric acid cycle and initial steps of oxidative 
phosphorylation 
 
 
 
Aldehydes to carboxylic acids 
Hypoxanthine-uric acid 
 
Catecholamine, neurotransmitters, and 
melanin synthesis 
 
 
Collagen synthesis, both dependent on 
ascorbic acid 
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Iron is also present as a component of iron-sulfur complexes in enzymes that are responsible for 
electron transport and energy generation in mitochondrial respiration and the citric acid cycle, and for 
ribonucleotide  reductase,  which  is  essential  for  DNA  synthesis  (Table  1).  Body  iron  content  is 
approximately 4.0 g in men and 3.5 g in women. In adults, most body iron is present in hemoglobin 
(60–70%)  in  circulating  erythrocytes  where  it  is  essential  for  oxygen  transport,  and  in  muscle 
myoglobin (10%). The remaining body iron (20–30%) is found primarily in storage pools located in 
the liver and reticulo-endothelial (macrophage) system as ferritin and hemosiderin. Only about 1% of 
body iron is incorporated in the range of iron-containing enzymes and less than 0.2% of body iron is in 
the plasma transport pool where it is bound to transferrin. 
4. Metabolism 
Absorption of iron from the gastrointestinal tract is regulated by the systemic need for iron. A series 
of organic molecules have specific roles in binding free iron, carrying it in the circulation, and delivering 
it to functional sites or, if not immediately needed, depositing it in a safe form in ferritin. The principal 
pool of ferritin is in the liver which holds approximately 25% of body iron: two-thirds as ferritin and 
up to one-third as insoluble hemosiderin. The body has no means of excreting excess iron. The only 
way in which iron is lost from the body is from desquamated skin cells and sweat (0.2–0.3 mg/day), 
urine (<0.1 mg/day), gastrointestinal secretions and hair and, in premenopausal women, from menses. 
Erythrocytes have a life span of approximately 120 days and are then engulfed and destroyed by the 
macrophages of the reticulo-endothelial system which recycle approximately 30 mg/day of iron from 
senescent erythrocytes. In healthy individuals obligatory iron losses from the skin and gastrointestinal 
mucosa  are  thought  to  be  approximately  1  mg/day  in  males  [3]  and  slightly  more  in  women  of  
child-bearing age because of additional losses due to menstruation, pregnancy, and lactation. 
5. Absorption 
Iron  uptake  and  transfer  depends  on  specific  cellular  carrier  mechanisms.  The  principal,  and 
probably  the  only,  physiological  and  primary  determinant  of  how  much  iron  is  absorbed  is  the 
systemic need for iron. Absorption occurs mainly in the proximal small intestine and involves the 
uptake and transfer of iron across the enterocyte into the systemic circulation. Carrier proteins are 
situated on the apical surface of the enterocytes, which is in contact with the intestinal lumen and its 
contents, and at their basal surface which is in contact with the circulation.  
There are at least two separate mechanisms for the uptake of heme and non-heme iron into the 
enterocyte.  The  divalent  metal  transporter  1  (DMT1)  transports  inorganic  iron  and  is  specific  for 
ferrous  iron.  Duodenal  cytochrome  B  reductase  (DcytB)  converts  dietary  ferric  iron  to  the  more 
soluble ferrous state. In the enterocyte, ferrous iron enters a labile or ―exchangeable‖ iron pool from 
which it can enter three different pathways, depending on the requirements of the body: taken into the 
local mitochondria for heme synthesis; sequestered into ferritin iron depots (and shed into the gut 
lumen at the end of the enterocyte’s lifespan); or transferred to the basal transporter (ferroportin 1) for 
translocation into the body. The mechanism of heme iron absorption remains unclear. The suggested 
role of the heme carrier protein 1 (HCP 1) in heme transport is now uncertain [4]. However, once in Nutrients 2011, 3  
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the enterocyte the heme molecule is degraded by heme oxygenase to release ferric iron [5] which then 
enters the enterocytic exchangeable pool. 
An efficient pathway exists for the intestinal uptake of ferritin, derived from plant and meat based 
dietary sources, which involves lysosomal dissolution of the ferritin core to release the iron [6–8]. 
Hephaestin, a ferroxidase found mostly in the basal membrane of enterocytes, is thought to facilitate 
basolateral iron export from the intestinal epithelial cells by oxidizing the ferrous iron back to its ferric 
form, possibly with ferroportin 1 [9]. Ceruloplasmin, which is found in plasma, is also a ferroxidase 
and may be involved in the oxidation of ferrous iron to ferric iron during binding to transferrin. 
Regulation of intestinal iron absorption occurs both at the stage of mucosal uptake and at the stage 
of its transfer to the blood. Changes in iron absorption are mediated by maturing enterocytes in the 
mucosal crypts and do not become effective until the newly matured enterocytes have moved to the 
villi,  resulting  in  a  time  lag  of  one  to  two  days  between  changes  in  systemic  iron  need  and  the 
corresponding mucosal setting for iron uptake and transfer. A large intake of dietary iron can, itself, 
induce the enterocytes to develop a ―mucosal block‖ [10], reducing the intestinal transfer of iron for 
several days [11] even in the presence of systemic iron deficiency.  
The principal regulator of iron absorption is hepcidin [12], predominantly expressed in the liver. It 
down regulates iron absorption in the small intestine,
 the transport of iron across the placenta, and the 
release of iron from macrophages and hepatocytes [13]. The mechanism of hepcidin action may be 
twofold and cell-type specific: in macrophages, it binds to and degrades ferroportin on the cellular 
membrane, which prevents iron from leaving the cell [14], however, in enterocytes it may also down 
regulate  iron  uptake  by  inhibiting  DMT1  transcription  [15,16].  Hepatic  hepcidin  production  is 
increased  when  iron  stores  are  adequate  or  high  and  during  inflammation.  When  systemic  iron 
requirements are increased or iron stores are low, or both, hepcidin production is decreased. Hepcidin 
production is also reduced by systemic hypoxia, stimulating the production of erythropoietin which 
induces  the  synthesis  of  new  red  blood  cells.  Defective  regulation  of  hepcidin,  or  its  receptor 
ferroportin, causes a range of iron overload disorders known as the hemochromatoses [17] (see Table 2), 
characterized by increased iron absorption, which leads to excessive systemic iron accumulation and 
overload. The most common form is associated with hepcidin deficiency. Hepcidin deficiency is a 
characteristic of mutations in the HAMP (hepcidin antimicrobial peptide) gene but most patients with 
genetic hemochromatosis have alterations in the HFE (high iron Fe) gene, or, rarely in the transferrin 
receptor 2 (TFR2) or hemojuvelin (HJV) genes, suggesting that these proteins are involved in the 
regulation of hepcidin synthesis [18]. 
6. Plasma Iron Transport 
Iron is distributed around the body in the circulation as transferrin. Transferrin comprises a core 
carrier  glycoprotein,  apotransferrin,  which  can  bind  one  or  two  atoms  of  ferric  iron  to  form 
holotransferrin, which is more usually referred to as transferrin. The uptake of iron by cells is mediated 
by the binding of holotransferrin (Tf) to transferrin receptors (TfR) on the cell surface which is then 
internalized  by  endocytosis.  The  iron  is  then  either  stored  as  ferritin  or  used  within  the  cell,  for 
example for hemoglobin synthesis. The apotransferrin and the TfR return to the cell surface and the 
apotransferrin  is  recycled  into  the  plasma.  A  second  transferrin  receptor  (TFR2)  is  thought  to  be Nutrients 2011, 3  
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involved  in  the  regulation  of  iron  absorption  by  influencing  hepcidin  expression.  Cells  may  also 
acquire iron through transferrin-independent pathways. The transmembrane protein, ―Stimulator of Fe 
Transport‖, facilitates the uptake of both ferrous and ferric iron independently of transferrin and may 
also  have  a  role  in  intracellular  iron  transport  [19–21].  Its  significance  in  iron  metabolism  is 
presently unclear. 
7. Iron Storage 
The liver is a major systemic depot of iron. Iron is taken up by hepatocytes from transferrin and 
released in times of increased need, subject to regulation by hepcidin. In diseases which cause increased 
transferrin iron saturation and iron overload (see Table 2) the liver continues to accumulate iron, even 
when iron stores are high, and is therefore vulnerable to developing damage secondary to iron overload.  
Table 2. Classification of genetic hemochromatoses. 
Type  Mutated 
protein 
Mode of 
transmission 
Phenotype  Mechanism  Severity  Relative incidence 
in populations of 
European origin 
1  HFE  Recessive  Parenchymal iron 
overload 
Hepcidin 
deficiency 
Highly 
variable 
Common 
(1 in 100–1 in 1000) 
 
2A Juvenile 
hemochromatosis 
Hemojuvelin  Recessive  Parenchymal iron 
overload. 
Early onset (2nd or 
3rd decades) 
 
Hepcidin 
deficiency 
Severe  Rare 
2B Juvenile 
hemochromatosis 
Hepcidin  Recessive  Parenchymal iron 
overload. 
Early onset (2nd or 
3rd decades) 
 
Hepcidin 
deficiency 
Severe  Rare 
3  Transferrin 
receptor 2 
Recessive  Parenchymal iron 
overload 
 
Hepcidin 
deficiency 
Severe  Rare 
4A (Ferroportin 
disease) 
Ferroportin 1  Dominant  Reticuloendothelial 
iron overload 
 
 
Functional 
deficiency of 
ferroportin 
Variable  Rare 
4B (Ferroportin 
disease) 
Ferroportin 1  Dominant  Parenchymal iron 
overload 
Ferroportin 
shows defective 
binding of 
hepcidin  
Variable  Rare 
Ferritin is the major intracellular storage protein found in all cells, with the highest concentrations 
in the liver, spleen and bone marrow. Ferritin binds iron as a ferric complex within a protein shell.  
Each molecule can theoretically store up to 4500 atoms of ferric iron but, in practice, it is typically less 
than 2000 atoms. The protein shell is penetrated by channels through which ferrous iron enters to Nutrients 2011, 3  
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interact with a ferroxidase at the centre of the molecule [22]. Iron is able to exit after it has been 
reduced. This iron depot is readily accessible for hemoglobin synthesis. Serum ferritin concentrations 
are normally within the range 15–300 µ g/L. They are lower in children than adults; from puberty to 
middle age, mean concentrations are higher in men than in women [23]. A close relationship exists 
between the total amount of storage iron and serum ferritin concentration in normal individuals [24], 
serum ferritin concentration of 1 µ g/L being equivalent to approximately 8 mg stored iron. 
8. Response to Iron Depletion 
Increased needs for iron are met initially by increased release of iron from ferritin. Both heme and 
non-heme  iron  absorption  are  inversely  related  to  serum  ferritin  concentrations  which  reflect  iron 
reserves [25]: Absorption of dietary iron increases as ferritin depots decrease. Intestinal uptake and 
transfer  responds  to  iron  depletion  in  humans  at  serum  ferritin  concentrations  of  approximately 
60 g/L [26]. If absorption is not adequate, tissue iron stores are slowly depleted, which is reflected in 
a reduction in circulating transferrin saturation. As a result, the delivery of iron to functional sites 
decreases  and  iron-dependent  functions,  such  as  erythropoiesis,  become  impaired,  leading  to  a 
decrease in hemoglobin concentration and the development of anemia. 
9. Inborn Errors of Iron Metabolism 
A number of sequence variations affect the genes coding for proteins involved in iron metabolism. 
The  majority  of  these  genetic  changes  need  to  be  present  in  two  corresponding  chromosomes 
(autosomal recessive). Although heterozygotes (i.e., individuals with one normal and one aberrant 
gene) have altered iron metabolism, this does not appear to affect their iron requirements or predispose 
them  to  excessively  accumulate  iron.  Hereditary  or  Genetic  Hemochromatosis  is  one  of  the  most 
common single gene disorders found in populations of North European origin. It is an autosomal 
recessive disease caused mainly by mutation of the gene coding for the HFE protein [27]. It results in 
excessive absorption of dietary iron, causing high levels of iron to accumulate in the body. This can 
cause organ damage, leading to clinical manifestations including diabetes, arthritis, and cirrhosis of the 
liver [28]. Two common variants of this gene, C282Y and H63D, have been identified. In the U.K., 
over 90% of patients with hereditary hemochromatosis are homozygous for C282Y. In Europe, the 
highest allele frequency of C282Y (10%) is found in Ireland, followed by the U.K., Brittany, and 
Scandinavia (around 8%); and the lowest in Italy (0.5%) [29,30]. The variant is virtually absent in 
populations of non-European origin. The clinical penetrance of homozygosity for C282Y is highly 
variable  and  the  majority  of  people  with  this  genotype  never  become  ill  as  a  result  of  iron  
overload [31–33]. The H63D variant is more widespread worldwide and has a less defined role in 
predisposing towards iron loading. Most compound heterozygotes do not develop iron overload [34]. 
Other types of genetic hemochromatosis are outlined in Table 2. 
―African Iron Overload‖ is caused by an unidentified genetic defect in iron metabolism combined 
with increased exposure to iron from contamination of drinks (e.g., beer) or food prepared or stored in 
ungalvanized  steel  containers  or  iron  cooking  pots.  In  contrast  to  the  hemochromatoses,  both 
heterozygotes and homozygotes appear to be affected [35].  Nutrients 2011, 3  
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10. The Effect of Infection and Inflammation on Iron Metabolism 
Acute and chronic inflammation affects the systemic distribution and turnover of iron: deposition of 
iron in tissue ferritin is increased, and availability of iron for distribution to functional sites, as well as 
gastrointestinal iron absorption, is reduced; concentrations of circulating iron are decreased and those 
of ferritin increased. This paradoxical situation, of red cell and systemic functional iron deficiency 
accompanied by increased systemic and macrophage iron deposits, can become sustained with chronic 
inflammatory conditions and is known as the anemia of chronic disease. Infection and inflammation 
are accompanied by an acute phase response which involves the hepatic synthesis and release of a 
series of proteins known as acute phase reactants. These include hepcidin, the key regulator of iron 
absorption and of its release from macrophages and hepatocytes [36], contributing to the development 
of  anemia  of  inflammation  by  reducing  iron  absorption  and  preventing  the  release  of  iron  from 
macrophages. Ferritin also is an acute phase reactant. In the anemia of chronic disease, serum ferritin 
concentrations  are  higher  than  those  of  individuals  with  similar  levels  of  tissue  iron  deposits  but 
without  infection  and  inflammation.  Chronic  disease  is  likely  to  be  a  significant  confounder  in 
population studies, and transient disturbances of iron metabolism in response to intercurrent infections 
need  to  be  considered  when  interpreting  the  standard  markers  of  iron  metabolism.  In  developing 
countries,  poverty,  malnutrition,  and  infection
 are  associated  with  the  acute  phase  response  and  a 
correspondingly high prevalence of anemia of chronic
 disease. 
11. Requirements 
Dietary reference values (DRVs) for iron are derived from limited data [37–40]. They are based on 
estimates of the amount of iron required to replace basal and menstrual iron losses, and for growth. 
The U.K. estimates are based on an assumed absorption of 15% from the diet. This percentage is 
derived from short-term studies carried out in iron replete individuals in whom iron absorption would 
be down regulated. Such studies do not allow for adaptive responses that occur over a longer time 
period than that needed for a single meal study, nor for the nature of this adaptation in response to 
systemic needs for iron. The DRVs for iron may be too high (particularly for girls and women of 
reproductive  age)  because  the  assumptions  about  the  amount  of  iron  absorbed  and  the  degree  of 
intestinal adaptation are cautious. There are currently insufficient new data to inform a reassessment of 
the DRVs for iron, however, improved understanding of iron metabolism could enable a reappraisal of 
existing data (Tables 3 and 4). 
Table 3. Dietary reference values for iron mg/day (µ mol/day 
1) [37].  
AGE  Lower reference nutrient 
intake (LRNI) 
Estimated average 
requirement (EAR) 
Reference nutrient 
intake (RNI) 
0–3 months  0.9 (15)  1.3 (20)  1.7 (30) 
4–6 months  2.3 (40)  3.3 (60)  4.3 (80) 
7–9 months  4.2 (75)  6.0 (110)  7.8 (140) 
10–12 months  4.2 (75)  6.0 (110)  7.8 (140) Nutrients 2011, 3  
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Table 3. Cont. 
1–3 years  3.7 (65)  5.3 (95)  6.9 (120) 
4–6 years  3.3 (60)  4.7 (80)  6.1 (110) 
7–10 years  4.7 (80)  6.7 (120)  8.7 (160) 
11–14 years (males)  6.1 (110)  8.7 (160)  11.3 (200) 
11–14 years (females)  8.0 (140) 
2  11.4 (200) 
2  14.8 (260) 
2 
15–18 years (males)  6.1 (110)  8.7 (160)  11.3 (200) 
15–18 years(females)  8.0 (140) 
2  11.4 (200) 
2  14.8 (260) 
2 
19–50 years (males)  4.7 (80)  6.7 (120)  8.7 (160) 
19–50 years (females)  8.0 (140) 
2  11.4 (200) 
2  14.8 (260) 
2 
50+ years  4.7 (80)  6.7 (120)  8.7 (160) 
1 1 µ mol = 55.9 µg ;  
2 COMA considered the distribution of iron requirements in women of child-bearing age to be skewed and 
the DRVs exclude those with high menstrual losses resulting in iron requirement above the EAR which is set 
at the 75th centile. 
The DRVs for infants aged zero to six months may be redundant because infants are born with 
sufficient systemic iron to meet their functional needs for their first six months. Therefore, they are not 
dependent  on  breast  milk  or  breast  milk  substitutes.  Evidence  from  randomized  controlled  trials 
suggests  that  a  delay  in  clamping  the  umbilical  cord  after  birth,  until  it  has  stopped  pulsing  
(about 2–3 min), is associated with higher systemic iron depots in the first six months of life. However 
it may also increase the risk of jaundice requiring phototherapy and it is not known if the beneficial 
effects are sustained [41]. 
Table 4. International dietary reference values for iron (mg/day). 
UK  
[37] 
USA and Canada  
[38] 
FAO/WHO  
[40] 
EU  
[39] 
Age  Recommende
d Nutrient 
Intake (based 
on 15% 
absorption) 
Age  Recommended 
Dietary 
Allowance 
(based on 18% 
absorption) 
Age  Recommend
ed Nutrient 
Intake (based 
on 15% 
absorption)
  
Recommende
d Nutrient 
Intake (based 
on 10% 
absorption
 
Age  Population 
Reference 
Intake (based 
on 15% 
absorption)
 
0–3 m
  1.7  -  -  -  -  -  -  - 
4–6 m  4.3  0–6 m 
1  0.27  -  -  -  -  - 
7–9 m  7.8  -  -  -  -  -  -  - 
10–12 m  7.8  7–12 m 
2  11.0  6–12 m 
5  6.2  9.3  6–12 m 
5  6.2 
1–3 y  6.9  1–3 y
  7.0  1–3 y  3.9  5.8  1–3 y  3.9 
4–6 y  6.1  4–8 y
  10.0  4–6 y  4.2  6.3  4–6 y  4.2 
7–10 y  8.7  -  -  7–10 y  5.9  8.9  7–10 y  5.9 
MALES                 
11–14 y  11.3  9–13 y
  8.0  11–14 y  9.7  14.6  11–14 y  9.7 
15–18 y  11.3  14–18 y
  11.0  15–17 y  12.5  18.8  15–17 y  12.5 
19–50 y  8.7  19–50 y
  8.0  18+ y  9.1  13.7  18+ y  9.1 
50+ y  8.7  50+ y
  8.0  -  -  -  -  - Nutrients 2011, 3  
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Table 4. Cont. 
FEMALES                 
11–14 y  14.8  9–13 y 
3  8.0  11–14 y 
6  9.3  14.0  11–14 y 
6  9.3 
15–18 y  14.8  14–18 y 
3  15.0  11–14 y  21.8  32.7  11–14 y  21.8 
19–50 y
  14.8  19–50 y
  18.0  15–17 y  20.7  31.0  15–17 y  20.7 
50+ y  8.7  50+ y
  8.0  18+ y  19.6  29.4  18+ y  19.6 
-  -  Pregnancy 
4  27.0  postmeno
pausal 
7.5  11.3  postmeno
pausal 
7.5 
-  -  Lactation 
(14–18 y)
 
10.0  lactating  10.0  15.0  lactating  10.0 
-  -  Lactation 
(19–50 y)
 
9.0  -  -  -  -  - 
m: months; y: years;  
1 No functional criteria of iron status have been demonstrated that reflect response to dietary intake in young infants. 
Thus, recommended intakes of iron are based on an Adequate Intake (AI) that reflects the observed mean iron intake of 
infants principally fed human milk;  
2 Based on 10% absorption;  
3 Based on assumption that girls younger than 14 years do not menstruate and that all girls 14 years and older do 
menstruate.  For  girls  under  age  14  who  have  started  to  menstruate,  it  would  be  appropriate  to  consider  a  median 
menstrual loss of 0.45 mg/day of iron. Therefore, the requirement is increased by approximately 2.5 mg/day of iron;  
4 The bioavailability in the first trimester is as estimated for non-pregnant females, in the second and third trimesters, it is 
increased to 25%;  
5 Bioavailability during this period varies greatly;  
6 Non-menstruating.  
12. Iron Status 
Iron status describes whether an individual has too little, enough or too much, iron in their body for 
their needs. A number of hematological and biochemical markers are used to assess iron deficiency, 
adequacy, or excess (Table 5). The markers are categorized according to whether they represent a 
functional  use  of  iron  (hemoglobin),  a  role  in  the  synthesis  of  hemoglobin  (zinc  protoporphyrin), 
supply of iron to tissues (iron bound to transferrin), iron depots in tissues (serum ferritin) or tissue 
needs  for  iron  (serum  transferrin  receptors)  (Table  6).  No  single  marker  of  iron  metabolism  is 
considered ideal for the assessment of iron deficiency or excess as all the individual indices have 
limitations  in  terms  of  their  sensitivity  and  specificity.  However,  in the  SACN  report  [1],  and  in 
agreement  with  international  practice  [42],  hemoglobin  (functional  iron)  and  serum  ferritin  (iron 
depots) were considered to be the most useful indicators of iron deficiency, adequacy, and excess. The 
WHO [43] criteria for identification of anemia, irrespective of cause, are; hemoglobin concentrations of: 
110 g/L in children under 5 years; 115 g/L in children 5–11.99 years; 120 g/L in children 12–14.99 years 
and non-pregnant females over 15 years; 130 g/L in males over 15 years. The WHO criteria used to 
define depleted storage iron are serum ferritin concentrations of: <12 µ g/L in children under 5 years; 
<15 µ g/L in males and females over 5 years. Nutrients 2011, 3  
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Table 5. A conceptual spectrum of iron status. 
Iron excess  Cellular and tissue architectural and functional damage 
  Increased tissue hemosiderin from degradation of ferritin 
Increased ferritin depots 
Reduced expression of transferrin receptors 
Iron adequacy  Reduced intestinal uptake and transfer of iron 
  Increased hepcidin 
Iron deficiency  Reduced hepcidin 
Increased expression of transferrin receptors 
Mobilization of depots, reduced ferritin levels 
Increased intestinal uptake and transfer of iron (possibly induced at 
serum ferritin levels <60 µ g/L) 
Reduced saturation of serum transferrin 
Functional defects in iron dependent activities 
Defective hemoglobin synthesis (increased zinc protoporphyrin) 
Reduced hemoglobin (anemia) 
Impaired muscle metabolism 
Secondary functional defects in the metabolism of other nutrients 
Cellular and tissue architectural and functional damage 
The reference ranges for markers of iron metabolism define iron sufficiency. They do not define 
iron deficiency or iron excess as the thresholds selected for use are not based on functional defects. For 
example,  low  serum  ferritin  concentrations  indicate  low  iron  depots  in  tissues  but  they  do  not 
necessarily represent a functional deficiency of iron. It is not clear at which level, above or below the 
reference range for serum ferritin, there is an increased risk of an adverse outcome. Similarly, the 
thresholds used to define anemia do not correspond to concentrations of hemoglobin below which 
functional consequences of anemia occur. Individuals with values either above or below the reference 
ranges  may  still  be  healthy.  The  reference  limits  only  indicate  the  possibility  of  iron  depletion, 
deficiency, or excess.  
Table 6. Markers used for assessment of body iron status (adapted from BNF [44]). 
Measurement  Representative 
reference range 
(adults) 
Confounding factors  Diagnostic use 
Functional iron       
Hemoglobin 
concentration 
  Males 
  Females  
 
Red cell indices 
  MCV *  
  MCH 
 
 
130–180 g/L 
120–160 g/L 
 
 
84–99 fl 
27–32 pg 
Other causes for anemia besides 
iron deficiency; a reciprocal 
relationship with iron stores 
should be expected in all anemias 
except in IDA. 
 
May be reduced in other disorders 
of hemoglobin synthesis  
(e.g., thalassaemia, sideroblastic 
anemias) in addition to ID. 
Assess severity of IDA; response 
to a therapeutic trial of iron 
confirms IDA. Not applicable to 
assessment of iron overload Nutrients 2011, 3  
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Table 6. Cont. 
Tissue iron supply       
Serum iron 
Saturation of transferrin 
 
 
 
Serum transferrin 
receptor 
 
 
Red cell zinc 
protoporphyrin * 
 
 
Red cell ferritin (basic) 
 
 
% hypochromic red 
cells 
10–30 mol/L 
16–50% 
 
 
 
2.8–8.5 mg/L ** 
 
 
 
70 mol/mol Hb 
(80 g/dL red 
cells) 
 
3–40 ag/cell 
 
 
<6% 
Normal short-term fluctuations mean 
that a single value may not reflect iron 
supply over a longer period. Both 
measures reduced in chronic disease. 
 
Directly related to extent of erythroid 
activity as well as being inversely 
related to iron supply to cells. 
 
Stable measures: reduced iron supply 
at time of red cell formation leads to 
increases in free protoporphyrin and 
hypochromic red cells, and reduced 
red cell ferritin. However, values may 
not reflect current iron supply 
 
May be increased by other causes of 
impaired iron incorporation into heme 
(e.g., lead poisoning, aluminium 
toxicity in chronic renal failure, 
sideroblastic anemias) 
Raised saturation of transferrin 
used to assess risk of tissue iron 
loading (e.g., in hemochromatosis 
or iron-loading anemias). 
 
Decreased saturation of 
transferrin, reduced red cell 
ferritin, increased zinc 
protoporphyrin, and increased 
serum transferrin receptors 
indicate impaired iron supply to 
the erythroid marrow.  
 
Serum transferrin receptors may 
have particular value in 
identifying early iron deficiency 
and, in conjunction with serum 
ferritin, distinguishing this from 
anemia of chronic disorders 
Iron in tissues       
Serum ferritin 
  Males 
  Females 
 
 
Tissue biopsy iron-Liver 
(chemical assay) 
 
 
 
Bone marrow (Perls’ 
stain) 
 
Quantitative 
phlebotomy 
 
Serum TIBC (may be 
measured directly or 
calculated from 
transferrin 
concentration) 
 
15–300 g/L 
15–200 g/L 
 
 
3–33 mol/g dry 
wt 
 
 
 
 
 
 
<2 g iron 
 
 
50–70 mol/L * 
 
 
 
 
 
 
Increased: as an acute phase protein 
and by release of tissue ferritins after 
organ damage. 
 
Potential for sampling error on needle 
biopsy, especially when this is <0.5 
mg, or liver is nodular. But remains 
the ―gold standard‖ in iron overload. 
 
 
 
 
 
 
 
 
 
 
 
 
All measures are positively 
correlated with iron stores except 
TIBC which is negatively 
correlated. Serum ferritin is of 
value throughout the range of 
iron stores. Quantitative 
phlebotomy, liver iron 
concentration, chelatable iron and 
MRI are of value only in iron 
overload. Bone marrow iron may 
be graded as absent, normal or 
increased and is most commonly 
used to differentiate ACD from 
IDA.  
 
In IDA, a raised TIBC is 
characteristic. 
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Table 6. Cont. 
Urine chelatable iron 
(after 0.5 g IM 
desferrioxamine) 
 
Non-invasive imaging 
MRI 
 
 
SQUID (Magnetic 
susceptibility) 
2 mg/24 h 
 
 
 
- 
 
 
 
 
 
 
Not yet sufficiently sensitive and reproducible 
for quantitation of normal levels of storage 
iron. Useful for detecting iron overload. 
 
Sensitive, accurate and reproducible but only a 
few machines in the world. 
 
ACD: Anemia of chronic disease; Hb: hemoglobin; IDA: iron deficiency anemia; MCV: Mean corpuscular volume; 
MCH: Mean corpuscular hemoglobin; MRI: Magnetic resonance imaging; TIBC: Total iron binding capacity;  
*  No  internationally  accepted  cut-off  values  for  MCV,  TIBC,  or  ZPP  have  been  developed  because  of  analytical 
differences between laboratories and because these indicators can be influenced by variations in the conditions under 
which  the  blood  samples  were  collected  (e.g.,  fasting/non-fasting,  time  of  day)  and  by  the  methods  used  for 
transportation, storage and processing;  
** There is a major problem with the different units and reference ranges for the various assays in use [45,46].  
13. Iron in the Diet 
Iron is present in foods as heme or non-heme iron. Heme iron is found almost exclusively in foods 
of animal origin as hemoglobin and myoglobin. Non-heme iron is found in animal and plant tissues, 
fortified  foods,  and  supplements.  The  most  important  determinant  of  dietary  iron  absorption  is 
systemic  iron  need:  more  iron is  absorbed  from  the  diet  in  a  state  of  iron  deficiency  and  less  is 
absorbed when iron depots are replete. 
13.1. Bioavailability 
Iron bioavailability refers to the proportion of iron that is taken up and transferred into the body by 
the intestinal mucosa and is used systemically. It is affected by the chemical form of iron. Heme iron is 
absorbed more efficiently from the diet than non-heme iron [47,48]. A number of dietary components 
have been shown to increase or reduce non-heme iron absorption from single test meals. The main 
enhancers of non-heme iron absorption are meat, and ascorbic acid found in fruit and vegetables. The 
main  inhibitors  of  non-heme  iron  absorption  are  calcium,  phytates  in  cereals  and  legumes,  and 
phenolic  compounds  found  in  tea,  coffee,  and  other  beverages.  However,  single  meal  absorption 
studies do not take account of adaptive absorptive responses to qualitative and quantitative changes in 
the  diet.  Studies  over  longer  periods  indicate  that  single  meal  studies  overestimate  the  effects  of 
enhancers and inhibitors of iron absorption [49–51]. This might be due to interactions between the 
various ligands for iron and their combined influence on mucosal uptake, and to mucosal adaptation. 
13.2. Models of Bioavailability  
Several models have been developed to estimate iron bioavailability from different meals and diets 
based on the serum ferritin concentration of the individual, the type of iron (heme or non-heme), and Nutrients 2011, 3  
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that take into account the presence of enhancers or inhibitors of iron absorption [52–54]. They have a 
number of limitations as they are based on iron absorption from single meals which may overestimate 
the effects of enhancers and inhibitors and do not take account of dietary complexity and variability or 
long-term  adaptation  to  iron  absorption.  For  example,  Beard  et  al.  [55]  compared  a  number  of 
prediction equations to the change in serum ferritin concentration of women taking part in a feeding 
trial  in  the  Philippines  to  assess  the  efficacy  of  iron  fortified  rice.  There  were  highly  significant 
differences in the predicted efficiency of iron absorption from six equations and none agreed with 
dietary iron utilization based on improvement in serum ferritin concentration. 
13.3. Epidemiology of Dietary Modulators and Iron Status 
The effects of dietary modulators of non-heme iron absorption on markers of iron status (usually 
hemoglobin and serum ferritin concentration) are difficult to ascertain in epidemiological studies due 
to the difficulty of obtaining accurate exposure data because of the quality of dietary assessments, 
limited  food  composition  data  for  some  modifiers  of  iron  absorption,  and  interactions  between 
enhancers and inhibitors of non-heme iron absorption. Observational studies are also affected by a 
number of confounding factors such as disease which can raise serum ferritin concentrations. Such 
studies have not shown a clear relationship between intakes of total iron or enhancers and inhibitors of 
iron  absorption  and  systemic  markers  of  iron  status,  although  most  cross-sectional  studies  have 
reported better iron status with increased meat intake [56–59] and heme iron intake [60–62]. 
13.4. Prospective and Intervention Studies 
Evidence from a limited number of prospective studies [e.g., 63,64] suggest that dietary inhibitors 
and enhancers of iron absorption do not substantially influence iron status. Long term intervention 
studies have also, overall, not shown a corresponding change in markers of iron status [e.g., 65–67]. A 
measurable effect of dietary modulators may only be observed in individuals with increased systemic 
iron needs and, as a consequence, higher absorptive capacity. Most intervention studies were carried 
out  in  iron  replete  western  populations  who  are  less  likely  to  have  a  physiological  response  to 
additional dietary iron. It is also possible that the lack of effect on serum ferritin concentration is 
because of relative insensitivity of serum ferritin concentration to changes in iron depots. This raises 
uncertainties regarding the importance of dietary advice in the U.K. and similar countries to maximize 
iron absorption: for example, eating cereal sources of iron with foods rich in vitamin C or avoiding 
drinking tea with meals. 
13.5. Anemia and Iron Deficiency 
There are no data to indicate that the bioavailability of dietary iron is a significant factor in the 
pathogenesis of anemia and iron deficiency in the U.K. population. U.K. diets contain a broad range of 
foods  containing  iron  and  various  enhancers  and  inhibitors  of  iron  absorption.  Consequently,  the 
bioavailability of dietary iron may have little influence on iron status in the U.K. population. Iron 
bioavailability may become a limiting factor in certain circumstances, for example, for individuals 
with an increased need of iron, particularly when the iron content of the diet is low [63]. The effects of Nutrients 2011, 3  
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enhancers and inhibitors of iron absorption may also be more important in developing countries where 
populations are at greater risk of iron intakes insufficient to meet requirements since diets are plant 
based, more limited and monotonous, contain higher levels of inhibitors, lower levels of enhancers, 
and less heme iron. Under these circumstances, the imbalance between requirements and absorption 
may lead to iron deficiency. 
13.6. Fortification 
Fortification of foods with iron has been the main approach used to increase the iron supply of the 
U.K.  population.  Iron  fortification  of  white  and  brown  wheat  flour,  to  replace  iron  lost  during 
processing, is mandatory in the U.K. A number of other foods, including breakfast cereals and breast 
milk substitutes are fortified on a voluntary basis. The iron compounds used for fortification of foods 
vary in their availability for intestinal uptake. Iron compounds which are relatively soluble, such as 
ferrous  sulfate,  are  not  widely  used  for  food  fortification  because  they  can  cause  unfavorable 
organoleptic changes during prolonged storage. Although elemental iron powders are less soluble they 
are more commonly used for fortification of foods, especially cereal products. This is because they are 
relatively inert and, since they do not react with the food vehicle used for fortification, they have a 
longer shelf life; they are also less expensive than other iron fortification compounds. Although iron 
fortified foods, especially cereals, make a substantial contribution to iron intakes in the U.K., evidence 
from  efficacy  trials  and  from  countries  with  national  fortification  policies,  e.g.,  Denmark  [59], 
Venezuela [68] and Brazil [69], suggests that foods fortified with elemental iron make little practical 
contribution to improving iron status, even in individuals with increased systemic iron needs, which is 
probably due to their low solubility and consequently low intestinal uptake. The usefulness of iron 
fortified breast milk substitutes in improving iron status of infants is also uncertain. 
13.7. Supplements 
Many non-heme iron supplements are available over the counter from chemists, supermarkets and 
health food shops. The most common forms are ferrous sulfate, ferrous fumarate, ferrous gluconate, 
ferrous glycine sulfate and iron polysaccharide [70]. The bioavailability differs but all are generally 
better  absorbed  than  slow-release  capsules  or  multivitamin/multimineral  supplements  [71].  Iron 
supplements are usually used as a short-term measure to provide extra iron when iron levels are low. 
Commercially  available  prophylactic  doses  used  to  prevent  deficiency  usually  range  between  
7–50 mg/day.  Supplemental  intakes  above  the  Guidance  Level  (an  approximate  indication  of  the 
amount of a nutrient that would not be expected to cause any adverse effects) of 17 mg/day are not 
advised  in  the  U.K.
  (Expert  Group  on  Vitamins  and  Minerals.)  [72].  During  pregnancy,  iron 
supplements are recommended for women with hemoglobin concentrations outside the normal U.K. 
range for pregnancy (i.e., 110 g/L during the first trimester and 105 g/L at 28 weeks) [73]. 
14. Consequences of Iron Deficiency  
Causes of iron deficiency include inadequate intakes of iron, impaired absorption, and increased 
blood losses due to menstruation or gastrointestinal disease [74–76]. Increased systemic need for iron Nutrients 2011, 3  
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leads  to  mobilization  of  iron  depots  from  macrophages  or  hepatocytes  and  upregulation  of  iron 
absorption. Progressive iron deficiency leads to anemia and reduced numbers of circulating precursor 
red cells and iron-dependent functions are affected. Anemia has been reported to have adverse effects 
on physical work capacity, pregnancy outcomes, and cognitive, motor and behavioral development 
in children. 
14.1. Work Capacity 
Evidence from animal and human studies suggests that decreases in hemoglobin concentration are 
associated with impairments in various aspects of physical work capacity (aerobic capacity, endurance 
capacity, energetic efficiency, voluntary activity, work productivity) [77]. The available data suggest 
functional defects associated with physical work capacity at hemoglobin concentrations at or below 
110–120 g/L and ferritin concentrations at or below 16–20 µ g/L. Human studies suggest that aerobic 
capacity is reduced at hemoglobin concentrations below about 110 g/L; however there is no clear 
evidence  that  iron  deficiency  in  the  absence  of  anemia  has  adverse  effects  on  aerobic  capacity 
[e.g., 78,79]. There is a limited amount of evidence suggesting that iron deficiency in the absence of 
anemia (hemoglobin >120 g/L; serum ferritin <16 µg /L) might impair endurance capacity, but this 
needs further substantiation. Overall there are insufficient data to assess the effects of iron deficiency 
or iron deficiency anemia on energetic efficiency, voluntary activity, or work productivity. There are a 
number of limitations with many of the human studies which assessed the relationship between iron 
and physical work capacity, including poor characterization of iron deficiency and an assumption that 
anemia  is  caused  by  iron  deficiency.  Additionally,  most  studies  were  carried  out  in  developing 
countries where there are multiple nutritional and socioeconomic deprivations which could confound 
the relationship between iron and physical work capacity. Clear thresholds associated with adverse 
outcomes cannot be determined because the data are presented discontinuously. 
14.2. Maternal Iron Status and Pregnancy Outcome 
Data from observational studies have suggested that maternal hemoglobin concentrations at either 
the low or high end of the distribution during pregnancy are associated with increased risk of adverse 
birth outcomes including low birth weight, preterm birth, and perinatal mortality [80]. However these 
are not necessarily causally related to iron supply or nutrition. The physiological changes that occur 
during pregnancy, such as plasma volume expansion and hemodilution, make it difficult to interpret 
the  markers  of  iron  metabolism  during  this  time  [81].  High  hemoglobin  concentrations  during 
pregnancy are generally not caused by high intakes of dietary or supplemental iron but are the result of 
inadequate plasma volume expansion, which is also associated with adverse birth outcomes [82–84]. 
Intervention studies of routine iron supplementation during pregnancy have not reported beneficial or 
adverse effects on pregnancy outcomes [85]. Evidence supports the recommendation made by the 
National Institute for Clinical Excellence (NICE) [73], that iron supplementation should not be offered 
routinely to all pregnant women but should be considered for women identified with hemoglobin 
concentrations below 110 g/L in the first trimester and 105 g/L at 28 weeks. Nutrients 2011, 3  
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14.3. Cognitive, Motor and Behavioral Development in Children 
Observational studies show that iron deficiency and iron deficiency anemia are usually associated 
with  many  psychosocial,  economic  and  biomedical  disadvantages,  which  can  independently  affect 
development. Iron deficient anemic young children usually have poorer development concurrently and 
in  the  future  than  non-anemic  children.  Measured  and  unmeasured  environmental  variables  could 
possibly explain these findings. 
Evidence from randomized controlled trials of iron supplementation suggests that iron deficiency 
anemia is a cause of poor motor development in children in the first three years of life but the long 
term effects are unknown [86,87]. There is insufficient evidence from rigorous randomized controlled 
trials to determine whether iron deficiency or iron deficiency anemia affects cognitive or language 
development in children three years or under. The relatively short duration of follow up in the trials 
may explain the lack of observed effect. There is evidence to suggest that iron treatment has beneficial 
effects on cognitive development in anemic older children, however it is not known whether these 
benefits are sustained [88–90]. Based on current evidence, it is not possible to derive thresholds of iron 
status at which cognitive, motor and behavioral development might be at risk, however risks appear to 
be lower at hemoglobin concentrations above 110 g/L. 
There are a number of difficulties in interpreting and comparing the data examining adverse effects 
of iron deficiency and iron deficiency anemia. This is because most studies have been conducted in 
developing countries where populations are associated with multiple nutritional deficiencies combined 
with social and economic deprivations. All these factors, which usually accompany iron deficiency, are 
potential confounders because they may be independently associated with adverse effects on physical 
work capacity, pregnancy outcomes, and cognitive, motor and behavioral development in children. 
Another difficulty is that iron deficiency and iron deficiency anemia is often poorly characterized in 
these studies: many only measure hemoglobin and assume this represents iron deficiency; another 
assumption is that dietary iron deficiency is the cause of this anemia rather than loss of iron secondary, 
for example, to blood loss. Additionally, sample sizes are small and different reference ranges and  
cut-off points have been used. 
15. Consequences of High Iron Intake and Burden  
Acute high doses of iron can cause intestinal mucosal damage and systemic toxicity [91]. Lower 
exposures  may  interfere  with  the  intestinal  uptake,  transfer,  and  systemic  use  of  copper  and  
zinc  [92,93].  High  systemic  iron  burden  is  also  associated  with  adverse  effects  arising  from 
degradation of tissue ferritin and subsequent free radical damage of surrounding tissues [94]. In the 
U.K., the evidence for adverse effects of iron was considered insufficient to establish a safe upper level  
(SUL—an  intake  that  can  be  consumed  daily  over  a  lifetime  without  significant  risk  to  health; 
established when supported by adequate data). Instead, a guidance level (GL—GLs are less secure 
than SULs because they are derived from limited data) of 17 mg/day of supplemental iron (i.e., in 
addition to dietary intake), based on gastrointestinal effects, was recommended for adults [72]. In the 
U.S., a tolerable upper intake level (UL—the Tolerable Upper Intake Level represents the highest level 
of daily nutrient intake that is likely to pose no risk of adverse health effects for almost all individuals Nutrients 2011, 3  
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in the general population) for total iron intake (from all sources) of 45 mg/day was set for adults, 
which was also based on gastrointestinal effects. A UL for iron has not been set in Europe as adverse 
gastrointestinal effects were not considered a suitable basis to establish a UL for iron from all sources 
and there were insufficient data regarding other risks. 
It has been proposed that high iron intakes or high body iron burden may increase the risk of 
colorectal  cancer  [95],  cardiovascular  disease  (CVD)  [96,97],  infection  [97],  neurodegenerative 
disorders [98], and inflammatory conditions [99]. The SACN report focused on the link between iron 
intakes/systemic iron, with colorectal cancer and CVD as these were considered to be the main issues 
of public health concern in the U.K. The report also considered effects of high exposures to iron on 
growth  in  iron  replete  children.  Other  conditions  that  have  been  associated  with  high  iron 
intake/systemic iron, e.g., Alzheimer’s disease, Parkinson’s disease, arthritis, and diabetes mellitus, 
were only briefly considered. 
15.1. Colorectal Cancer 
There is a limited amount of epidemiological data on the association between iron intakes and high 
iron depots on colorectal cancer risk [100]. The available data suggest that: increased dietary intakes of 
total or heme iron might be associated with increased colorectal cancer risk, however confounding by 
other  dietary  and  lifestyle  factors  is  possible;  high  iron  depots  are  not  associated  with  increased 
colorectal cancer risk; and heterozygosity for hereditary hemochromatosis might be associated with 
increased colorectal cancer risk but it is not clear if this is related to iron. Overall, there are insufficient 
data on the association between colorectal cancer risk and dietary intakes of total iron, heme iron, iron 
status, or heterozygosity for hereditary hemochromatosis, to reach clear conclusions. 
Meat,  particularly  red  meat,  is  almost  exclusively  the  source  of  heme  iron.  In  their  report, 
Nutritional Aspects of the Development of Cancer [2], COMA concluded that there was moderately 
consistent  evidence,  from  cohort  studies,  of  a  relationship  between  red  and  processed  meat 
consumption and colorectal cancer. The substantial body of prospective epidemiological data that has 
accumulated since the COMA report in 1998 consistently indicates an increased colorectal cancer risk 
associated with high intakes of red and processed meat [100]. Overall, the available epidemiological 
evidence suggests that red and processed meat intake is probably associated with increased colorectal 
cancer risk. The evidence for an increased colorectal cancer risk is not unequivocal since it is based on 
prospective  observational  studies,  so  effects  of  confounding  by  other  dietary  or  lifestyle  factors 
associated with meat consumption and colorectal cancer risk cannot be excluded. Although a number 
of plausible biological mechanisms have been proposed to explain the association between red meat 
and colorectal cancer risk, none are supported by robust evidence. It is not possible to identify if there 
is  a  dose-response or  a threshold level  of red and  processed  meat which  may be  associated with 
increased colorectal cancer risk because of a number of limitations in the data. 
15.2. Cardiovascular Disease 
The available epidemiological evidence on total iron intake or body iron and CVD does not suggest 
an association [101,102]. The evidence examining the association between heme iron intake and CVD 
risk is limited to a few studies which suggest overall that high intakes of heme iron are associated with Nutrients 2011, 3  
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increased  CVD  risk.  However  it  is  possible  that  this  could  be  due  to  other  components  of  meat  
(the main source of heme iron) associated with CVD risk, such as saturated fats or other dietary and 
lifestyle factors associated with meat intake. Studies of HFE heterozygosity and CVD risk suggest that 
C282Y heterozygotes (but not H63D heterozygotes) may be at increased risk of CVD, but there are 
insufficient data to reach clear conclusions [103]. 
15.3. Growth 
Iron  supplementation  may  have  a  negative  effect  on  the  physical  growth  of  iron  replete  
(hemoglobin >110 g/L; serum ferritin >12 µg /L) infants and children [87,104,105] but further studies 
are required to characterize this effect.  
15.4. Other Consequences 
There is insufficient evidence to suggest that high iron intake or high iron depots increase the risk of 
diabetes  mellitus  in  the  general  population  or  that  homozygosity  or  heterozygosity  for  hereditary 
hemochromatosis increases diabetes risk. The limited amount of evidence for an association between 
iron intake and rheumatoid arthritis is inconclusive. There is no evidence that dietary iron is associated 
with Parkinson’s disease or Alzheimer’s disease. 
16. Effect of Iron Deficiency and Excess on Immunity and Infection 
Evidence from animal studies suggests that iron plays a role in immunity and infection. Human 
studies have shown that iron deficiency anemia (typically defined as hemoglobin <100 g/L plus 1 or 
more measure of iron deficiency) [106–108] and iron overload (due to multiple blood transfusions) 
impair some aspects of immune function [109,110]. However it is not known if these impairments 
increase susceptibility to infectious pathogens.  
Supplements 
Although  it  has  been  proposed  that  iron  supplementation  may  decrease  resistance  to  infection, 
evidence suggests that it does not increase the risk of non-diarrheal or respiratory tract infections in 
children but may increase diarrhea risk [104,111]. It is not clear if iron supplementation increases risk 
of malaria or risk of infectious diseases in areas where malaria incidence is high [112–115]. There is 
currently insufficient evidence to draw conclusions on the relationship between iron supplementation 
and HIV or tuberculosis. Most human studies on iron and infection have been conducted in developing 
countries  where  multiple  nutrient  deficiencies  co-exist  and  which  may  also  affect  resistance  to 
infection.  There  is  no  evidence  to  suggest  that  iron  supplementation  would  have  any  effect  on 
infectious disease incidence or morbidity in the U.K. However iron supplementation may have adverse 
effects  in  some  subgroups  of  the  population,  for  example,  those  with  HIV  or  children  at  risk  of 
diarrhea [115–116]. Nutrients 2011, 3  
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17. Dietary Iron Intakes and Status in the U.K.  
The National Diet and Nutrition Survey (NDNS), in a series of separate cross-sectional surveys of 
different age groups, and the Low Income Diet and Nutrition Survey (LIDNS) [117–124] provide 
nationally representative data on iron intakes and iron status in the U.K. for the general population and 
low  income  populations  respectively.  However  there  are  difficulties  associated  with  using  dietary 
surveys  to  assess  the  adequacy  of  nutrient  intakes  against  DRVs,  including  reliability  of  food 
composition tables and misreporting of food consumption. Additionally, assessment of the adequacy of 
iron intakes against DRVs only takes limited account of the amount of iron absorbed from the diet. 
The WHO thresholds for iron deficiency (based on serum ferritin concentration) and anemia (based on 
hemoglobin concentration) were used to identify the prevalence of iron deficiency and iron deficiency 
anemia in the U.K. However, data on hemoglobin and serum ferritin values should be interpreted with 
caution  since  neither  marker,  alone  or  in  combination,  necessarily  diagnose  iron  deficiency  but 
indicate individuals at risk of deficiency. 
Although the NDNS is now a continuous rolling programme of people aged 18 months and over 
living in the U.K. and intake data from year 1 (2008/9) have been published [125], they were not used 
to assess adequacy of intakes/status because the sample size of intake data is currently too small for 
robust subgroup analysis and the blood status data have not yet been published because the sample size 
is currently too small for meaningful analysis. 
Data from the NDNS series and LIDNS show that iron fortified cereals, including bread, are the 
main contributors and contribute about half of the iron intake of most of the population in the U.K. 
(Tables 7 and 8). The contribution that fortified foods make to the supply of absorbed iron available 
for uptake, transfer and systemic utilization, and their effect on iron status in the U.K. is not known. 
Meat and meat products and vegetables also make substantial contributions to dietary iron intakes. 
Although heme iron is more bioavailable than non-heme iron, the NDNS did not find any significant 
associations between heme iron and markers of iron status (serum ferritin and hemoglobin). 
Table 7. NDNS—Contribution (%) of food types to average daily intake of total iron. 
    Children 
1½–4½ 
Young people 
4–18 years 
Adults 
19–64 years 
Adults 65+ 
Free-living 
Adults 65+ 
Institutions 
    Males  Females  Male  Females  Males  Females  Males  Females  Males  Females 
Cereals    49  48  55  51  44  45  48  47  50  50 
white bread  8  8  11  11  10  8  10  9  10  10 
wholemeal bread  3  3  2  2  3  3  7  7  5  6 
soft grain and other 
bread 
-  -  -  -  3  3  -  -  -  - 
whole grain and high 
fibre breakfast 
cereals 
11  10  12  9  12  13  10  12  8  9 
other breakfast 
cereals 
10  10  17  14  6  7  5  5  9  8 
biscuits, buns, cakes, 
pastries 
5  5  6  8  4  5  8  8  10  10 Nutrients 2011, 3  
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Table 7. Cont. 
Milk and milk products  6  6  3  3  1  1  3  4  4  5 
Eggs and egg dishes  2  3  2  2  3  3  3  3  4  4 
Fat spreads    0  0  0  0  0  0  0  0  0  0 
Meat and meat products  14  14  14  13  19  15  18  16  17  15 
Fish and fish dishes  2  2  1  2  2  3  3  2  2  2 
Vegetables (excluding potatoes)  7  7  7  8  9  11  8  10  8  8 
Potatoes and savory snacks  7  7  7  7  7  8  7  7  5  5 
Fruit and nuts    3  3  1  2  2  3  3  3  3  3 
Sugars, preserves, confectionery  4  3  4  4  2  2  1  1  1  1 
Drinks    3  3  1  2  7  6  3  3  1  1 
Misc    2  2  2  2  3  3  3  4  5  6 
Total no respondents (w)  -  -  -  -  833  891  540  735  93  319 
Total no respondents (unw)  848  827  856  845  766  958  632  643  204  208 
* includes soft drinks, alcoholic drinks, tea, coffee and water;  
** includes powdered beverages (except tea and coffee), soups, sauces, condiments and artificial sweeteners.  
Table 8. The Low Income Diet and Nutrition Survey (LIDNS)—Contribution (%) of food 
types to average daily intake of total iron. 
  Children (2–10 years)  Adults (19 years and over) 
  Boys  Girls  Men  Women 
Cereals and cereal products  53  49  40  41 
Milk and milk products  2  2  1  1 
Eggs and egg dishes  2  2  4  3 
Fat spreads  0  0  0  0 
Meat and meat products  17  16  23  21 
Fish and fish dishes  1  2  2  3 
Vegetables excluding potatoes  7  8  10  10 
Potatoes and savory snacks  10  11  8  9 
Fruit and nuts  1  2  2  2 
Sugars, preserves and confectionery  3  3  2  2 
Drinks *  1  2  5  4 
Miscellaneous **  2  2  3  4 
Total no. respondents (unw)  439  493  946  1850 
* includes soft drinks, alcoholic drinks, tea, coffee and water;  
** includes powdered beverages (except tea and coffee), soups, sauces, condiments and artificial sweeteners.  
17.1. Total Iron Intakes 
Average iron intakes in the general population are near (>90%) or above the reference nutrient 
intake (RNI- the RNI represents the amount of a nutrient that is likely to meet the needs of 97.5% of 
the population) for most population groups in the U.K. (Table 9). Intakes below 90% of the RNI were 
reported in a high proportion of children aged 1½–3½ (73–81%), girls aged 11–18 years (60%) and 
women aged 19–49 years (66–87%). Population groups with substantial proportions below the lower 
reference nutrient intake (LRNI—the LRNI represents the amount of a nutrient that is likely to meet Nutrients 2011, 3  
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the needs of 2.5% of the population) were children aged 1½–3½ (12–24%), girls aged 11–18 years  
(44–48%) and women aged 19–49 years (25–40%). 
Table 9. NDNS—Total mean (median) iron intake from all sources and food sources. 
  MALE  FEMALE 
Age (years)  Mean (median) 
intake—all 
sources, 
mg/day 
Mean (median) 
intake—food 
sources, 
mg/day 
Base 
(w) 
Base 
(unw) 
Mean (median) 
intake from all 
sources, 
mg/day 
Mean (median) 
intake food 
sources, 
mg/day 
Base 
(w) 
Base 
(unw) 
Children 
1.5–4.5 
5.7 (5.4)  5.5 (5.4)   
- 
 
848 
5.4 (5.0)  5.2 (5.0)   
- 
 
827 
1.5–2.5 *  5.0 (4.7)  4.9 (4.7)  -  288 **  5.0 (4.7)  4.9 (4.7)  -  288 ** 
2.5–3.5 *  5.6 (5.4)  5.4 (5.3)  -  303 **  5.6 (5.4)  5.4 (5.3)   -  303 ** 
3.5–4.3  6.2 (5.9)  6.1 (5.9)  -  250  5.9 (5.5)  5.6(5.5)  -  243 
                 
Young people 4–18  10.5 (9.9)  10.4 (9.8)  3331  856  8.5 (8.0)  8.3 (7.9)  3159  845 
4–6  8.3 (8.0)  8.2 (7.9)  1134  184  7.4 (7.1)  7.3 (7.1)  656  171 
7–10  9.8 (9.3)  9.7 (9.3)  912  256  8.5 (8.2)  8.4 (8.2)  866  226 
11–14  10.8 (10.4)  10.8 (10.4)  870  237  9.1 (8.6)  8.8 (8.4)  821  238 
15–18  12.6 (11.7)  12.5 (11.6)  861  179  8.9 (8.2)  8.7 (8.0)  816  210 
                 
Adults 19–64  14 (12.9)  13.2 (12.6)  833  766  11.6 (10.0)  10.0 (9.6)  891  958 
19–24  11.5 (11.3)  11.4 (11.2)  108  61  10.0 (9.3)  8.8 (9.1)  104  78 
25–34  13.9 (12.8)  13.0 (12.5)  219  160  9.8 (9.0)  9.2 (9.0)  210  211 
35–49  14.1 (13.2)  13.7 (13.1)  253  303  12.9 (10.5)  10.2 (10.1)  318  379 
50–64  15.2 (13.6)  13.6 (13.3)  253  242  12.3 (11.0)  10.9 (10.6)  259  290 
                 
Adults 65 and over                 
Free-living  11.6 (10.6)  11.0 (10.5)  540  632  8.9 (8.4)  8.6 (8.3)  735  643 
65–74  11.9 (10.6  11.1(10.5)  353  271  9.3 (8.7)  9.0 (8.6)  409  256 
75–84  11.1 (10.7)  10.8 (10.5)  160  265  8.5 (8.1)  8.4 (8.1)  249  217 
85+  10.6 (9.7)  10.4 (9.7)  26  96  7.9 (7.6)  7.7 (7.5)  77  170 
                 
Institutionalized  9.6 (9.3)  9.6 (9.3)  93  204  8.3 (7.9)  8.2 (7.9)  319  208 
65–84  9.6 (9.2)  9.6 (9.2)  57  128  8.7 (8.1)  8.6 (8.1)  144  91 
85+  9.7 (9.3)  9.6 (9.3)  36  76  8.0 (7.7)  7.8 (7.6)  174  117 
                 
* Data reported for boys and girls combined 
** Half of the base figure for the sum of boys and girls as data combined in report. 
In low income groups average daily intakes were above the RNI for all males. For females, average 
intakes of iron were at or above the RNI for girls aged 2–10 years and women aged 65 years and over; 
mean daily intakes were below the RNI for girls aged 11–18 years (63% of RNI) and women aged  
19–49 years (about 60% of RNI). A high proportion of females aged 11–49 years (39% of girls aged 
11–18 years; 50% women 19–49 years) had intakes below the LRNI. Nutrients 2011, 3  
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17.2. Hemoglobin 
Groups  with  the  highest  prevalence  of  hemoglobin  concentrations  below  WHO  thresholds  for 
anemia in the general U.K. population were adults aged 65 years and above living in institutions  
(39–52%), free-living adults aged 75 years and over (13–38%), and girls aged 4–6 years (15% based 
on higher threshold of 115 g/L; 9% based on lower threshold of 110 g/L). In low income groups the 
highest proportions of adults with hemoglobin concentrations below the WHO cut-offs were men aged 
65 years and above (20%). 
17.3. Serum Ferritin 
In  the  general  population  substantial  proportions  of  children  aged  1½–4½  years,  girls  aged  
11–18 years, women aged 19–24 years and 35–49 years, and free living adults 75 years and over, had 
serum ferritin concentrations below WHO thresholds indicating an increased risk of iron deficiency. 
In low income groups, women aged 19–49 years were at greatest risk of iron deficiency. 
17.4. Iron Deficiency Anemia 
In  the  general  population,  risk  of  iron  deficiency  anemia  (hemoglobin  and  serum  ferritin 
concentration below WHO thresholds) was highest (5–6%) for children aged 1½–2½ years, girls aged  
15–18 years, women aged 35–49 years, men 65 years and over living in institutions, and free living 
adults  aged  85  years  and  over.  In  low  income  groups,  a  substantial  proportion  of  women  aged  
19–39 years were at risk of iron deficiency anemia (9–11%). 
Although  data  from  the  NDNS  and  LIDNS  suggest  that  considerable  proportions  of  some 
population groups may have iron intakes below amounts required to meet their requirements, this is 
not clearly consistent with the iron status data which suggests that for 95% of the general population, 
current intakes are adequate to maintain their iron status above internationally accepted criteria for iron 
deficiency anemia. The mismatch between the iron intake and iron status data suggests that the DRVs 
for iron may be too high. The DRVs are based on limited data and may not take full account of 
absorptive adaptation to increased iron needs. 
The NDNS and LIDNS both broadly show that women aged 15–50 years are at increased risk of 
iron deficiency anemia which is consistent with iron losses in this age group due to menstrual blood 
loss. More women of reproductive age from low income groups are at risk of iron deficiency anemia 
compared to those in the general population. The reasons for this are not clear as mean iron intakes are 
similar. It is possible that intakes are insufficient to compensate for higher pregnancy burden and/or 
greater ill health in women from low income groups. Iron deficiency anemia observed in some adults 
aged 65 years and over might be caused by decreased absorption of dietary iron due to gastric atrophy 
or increased blood loss due to gastrointestinal disease or medication. There are no data to clarify the 
etiology of iron deficiency in the U.K. population.  
Although data from NDNS and LIDNS suggest that iron intake and iron status in the U.K. may be 
of public health concern for toddlers, women of reproductive age, and adults aged 65 years and over, 
this is dependent on the confidence placed on the DRVs for iron intake which are based on cautious Nutrients 2011, 3  
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assumptions and on iron status criteria for iron deficiency and iron deficiency anemia which are not 
based on functional defects. 
18. Potential Impact of Reducing Total Red Meat Consumption on Iron and Zinc Intake 
A modeling exercise (based on intake data from the 2000/1 NDNS of adults age 19–64 years) to 
explore the potential effect of reducing total red (including processed) meat consumption on intakes of 
iron and zinc, suggests that red meat makes a greater contribution to total zinc intake from all foods  
(32% for men; 27% for women) than to total iron intakes (12% for men; 9% for women). In 2000/1 the 
average consumption of total red meat (consumers of red meat only) in the U.K. was approximately 
70 g/day (cooked weight) (88 g/day, men; 52 g/day, women). This is lower than the previous estimate 
of average total red meat intake of 90 g/day cited in the 1998 COMA report [2] because the COMA 
figure included non-meat components of composite dishes such as meat products (e.g., sausage rolls, 
pies) and meals containing red meat (e.g., lasagna, stew) resulting in an overestimation of red meat 
consumption. In 2000/1, the average total red meat intake of consumers in the 75th percentile of the 
distribution  of  intakes  was  approximately  94  g/day  cooked  weight  (115  g/day  for  men;  70  g/day 
for women). 
Preliminary findings from the first year (2008/9) of the NDNS rolling program suggest that current 
consumption of red meat is approximately 10 g/day higher than it was in 2000/1. However, these 
findings should be interpreted with caution because there are important insecurities in the data (see full 
SACN report for further details). 
The modeling data suggest that reducing the red and processed meat intakes of consumers in the 
upper ranges of the distribution down to an average of 80 g/day would have a minimal impact on the 
proportion of individuals with average intakes below the LRNI for iron and zinc. Further reductions in 
the total red meat intake of consumers to an average of 70 g/day would have little effect on iron intakes 
but the proportion of men with intakes of zinc below the LRNI may increase from 3.7% to 5.5%. 
19. Summary  
There are a number of uncertainties which complicate a risk assessment of iron and health. The 
main sources of uncertainty are: lack of definitive data on the amounts of heme and non heme in the 
diet, difficulties in assessing dietary iron intakes, poor correlation between intakes and systemic iron 
load, difficulty in measuring adaptive and functional responses to variations in iron intake, uncertain 
and possibly conservatively high estimates of DRVs, lack of sensitive and specific markers to assess 
iron deficiency or excess, lack of consistent quality control and reference values in measurement of 
customary markers of iron status, inadequate characterization of the role of iron deficiency anemia and 
the relative role  of iron deficiency and  other causes  of anemia in  studies  investigating  the health 
consequences of iron deficiency, small sample sizes in most studies, and confounding by other dietary 
and  lifestyle  factors  and  by  alterations  in  iron  metabolism  in  response  to  infection.  All  these 
uncertainties make it difficult to determine dose-response relationships or confidently characterize the 
risks associated with iron deficiency or iron excess. Nutrients 2011, 3  
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20. Recommendations 
The following are the main recommendations of the SACN report on Iron and Health [1]: 
  It is important to ensure that the UK population has a safe and adequate supply of iron to meet 
physiological requirements. It is recommended that a public health approach to achieving adequate 
iron status should emphasise the importance of a healthy balanced diet that includes a variety of 
foods containing iron. Such an approach is more important than focusing on particular inhibitors or 
enhancers of the bioavailability of iron from diets. 
  While  substantial  proportions  of  the  UK  population  appear  to  have  iron  intakes  below  dietary 
recommendations for iron, this is not clearly consistent with the low prevalence of poor iron status 
(see next paragraph). This might be because there are important uncertainties in the DRVs for iron 
intake  which  may  be  too  high,  particularly  for  girls  and  women  of  reproductive  age.  It  is 
recommended  that  the  DRVs  for  iron  should  be  reviewed  when  more  data  become  available  
(see research recommendations).  
  Although there are many uncertainties in the data, about 95% of the UK population is iron replete 
(haemoglobin and serum ferritin concentrations above the WHO thresholds used to define iron 
deficiency  and  anaemia).  However  some  population  groups  may  be  at  risk  of  iron  deficiency 
anaemia (WHO criteria for iron deficiency are serum ferritin concentrations below the following 
thresholds: children under 5 years, 12 µ g/L; males and females 5 years and over, 15 µ g/L. WHO 
criteria for anaemia are haemoglobin concentrations below the following thresholds: children under 
5 years,  110 g/L;  children  5–11.99  years,  115  g/L;  children  12–14.99  years  and  non-pregnant 
females over 15 years, 120 g/L; males over 15 years, 130 g/L). These include toddlers, girls and 
women of reproductive age (particularly those from low income groups) and some adult groups 
aged over 65 years. It is recommended that health professionals be alert to the increased risk of iron 
deficiency anaemia in these groups. Those with signs and symptoms suggestive of iron deficiency 
anaemia should receive appropriate clinical assessment and advice, including dietary advice on how 
to increase their iron intakes and to consider use of iron supplements if required. 
  Current evidence does not support routine iron supplementation of pregnant women but this should 
be  kept  under  review.  The  recommendation  by  NICE  (2008)  is  therefore  supported,  that  iron 
supplementation should not be offered routinely to all pregnant women but should be considered for 
women identified with haemoglobin concentrations below 110 g/L in the first trimester and 105 g/L 
at 28 weeks. 
  Red and processed meat is a source of iron in the diet of the UK population. COMA reported 
possible links between red and processed meat consumption and colorectal cancer risk in 1998 and 
the evidence that has accumulated since then generally supports this association. However, it is not 
possible to quantify the amount of red and processed meat that may be associated with increased 
colorectal cancer risk because of limitations and inconsistencies in the data. It may be advisable for 
adults with relatively high intakes of red and processed meat (e.g., it is estimated that those above 
the 75th percentile consume over 90 g/day) to consider reducing their intakes. Evidence from a 
theoretical modelling exercise indicates that a reduction in the red and processed meat intakes of 
high consumers, to the population average for adult consumers (about 70 g/day cooked weight in 
2000/01), would have little impact on the proportion of the adult population with iron intakes below Nutrients 2011, 3  
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the  LRNI.  However,  this  estimate  is  based  on  data  from  2000/01  and  will  need  to  be  kept 
under review. 
Research Recommendations 
The following are the main recommendations of the SACN report [1] for further research: 
  A  more  coordinated  approach  to  research  on  iron  in  the  U.K.  and  elsewhere  is  required  to 
characterize iron status involving harmonization of reference ranges and analytical quality control 
for  markers  of  iron  metabolism.  Consistent  study  designs  and  protocols  will  enable  better 
characterization of function thresholds in relation to iron sufficiency, deficiency, or excess. This 
would improve the cost benefits of the research and enable research findings to be more relevant to 
public health needs. 
  Good quality dose-response data are required to enable a reassessment of the dietary reference 
values for iron. Knowledge of the systemic regulation and mediation of iron homeostasis should be 
applied to characterize better the responses to increased and reduced systemic needs for iron and the 
development, or better validation, of existing markers used to assess the adequacy of iron status in 
populations and individuals. 
  Future studies assessing the relationship between iron excess and chronic disease should employ a 
standardized approach to measure iron exposure and categorization of red and processed meat and 
other sources of organic and inorganic iron. This, together with the maintenance and expansion of 
food composition databases, with particular reference to iron content, would improve the quality of 
dietary assessments of iron intake for studies relating to iron and chronic disease. Assessments of 
systemic iron depots in such studies should be based on measurement of serum ferritin concentration. 
  Iron intakes and iron status of vulnerable groups, particularly minority ethnic groups and infants 
aged up to 18 months, need to be better characterized.  
  An  improved  understanding  is  required  of  the  factors  underlying  differences  in  risk  of  iron 
deficiency anemia between women of reproductive age from low income populations and those in 
the general population. 
  The extent to which foods fortified with iron, e.g., cereals and cereal products, and breast milk 
substitutes  contribute  to  the  supply  of  absorbed  iron  and  to  achieving  adequate  iron  status, 
particularly in vulnerable groups, should be assessed. 
  An improved understanding  of  the possible adverse effects  of iron supplements  in iron replete 
children is needed. 
  Further randomized controlled trials with adequate power and sufficient duration are required to 
examine the effect of iron supplementation on mental development in children under three years old 
with iron deficiency anemia. 
  Further studies are required on benefits, risks, and long-term effects of a delay in clamping the 
umbilical cord after birth until it has stopped pulsing. Nutrients 2011, 3  
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